Company / R&D Expense
iRhythm Holdings, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$84.6M
FY2025
5-year range
$38.7M / $84.6M
FY2021-FY2025
Trend
+18.4%
vs FY2024
Sector context
#62 of 105
Health Care
What the data says
At $85M, iRhythm Holdings, Inc.'s r&d expense ranks #62 of 105 in the Health Care sector. R&D Expense has increased for 4 consecutive years, from $39M in FY2021 to $85M in FY2025.
Based on SEC 10-K filings.
$85M in FY2025 with a 5-year CAGR of +15.4%.
Improved from $60M to $85M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +22.0%
- 5-Year CAGR
- +15.4%
- 10-Year CAGR
- -
Sector benchmark
#62 of 105 in Health CareTop 59% of 105This company $84.6M Sector average $284.2M
▼
-70.2% below sector average
Key checks
Key Insights
- iRhythm Holdings, Inc.'s r&d expense has grown for 4 consecutive years.
- 5-year CAGR of +15.4%, indicating consistent growth.
- In FY2025, r&d expense increased 18.4% year-over-year.
- Ranks #62 out of 105 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.35 (distress zone, below 1.8 threshold)
- Negative profit margin: -19.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $84.6M | +18.4% |
| FY2024 | $71.5M | +18.6% |
| FY2023 | $60.2M | +29.3% |
| FY2022 | $46.6M | +20.5% |
| FY2021 | $38.7M | -6.4% |
| FY2020 | $41.3M | +10.8% |
| FY2019 | $37.3M | +78.8% |
| FY2018 | $20.9M | +57.3% |
| FY2017 | $13.3M | +85.5% |
| FY2016 | $7.2M | +12.6% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026